Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More
Portfolio Pulse from Lara Goldstein
The article discusses recent developments in the field of psychedelic medicine, including new data from MAPS PBC's Phase 3 clinical study of MDMA-assisted therapy for PTSD, a study suggesting that combining MDMA with psilocybin or LSD could reduce difficult trips, and the House Rules Committee's vote on psychedelics amendments. It also mentions Scotland's approval of a pilot safer drug consumption site, and various milestones in the psychedelic drugs market. The article also provides an update on the performance of the AdvisorShares Psychedelics ETF (PSIL) and several psychedelic stocks.
September 18, 2023 | 10:06 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
atai Life Sciences (ATAI) closed at $1.45, slightly up from $1.43 on Friday 8 but down from $1.53 on Friday 1.
The stock price of atai Life Sciences has shown minor fluctuations over the week, suggesting a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
NEUTRAL IMPACT
COMPASS Pathways (CMPS) closed at $9.41, the same as the last two Fridays.
The stock price of COMPASS Pathways has remained stable over the week, suggesting a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
NEUTRAL IMPACT
The AdvisorShares Psychedelics ETF (PSIL) opened at $1.75 on Monday, Sept. 11 and closed at $1.74 on Friday 15. The ETF's yearly price range has been changed to between $3.24 and $1.62.
The ETF's price has remained relatively stable over the week, suggesting a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Clearmind Medicine (CMND) raised $2.25M in a public offering.
The successful public offering by Clearmind Medicine could boost investor confidence, suggesting a positive short-term impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Lucy Scientific Discovery (LSDI) is preparing for the global wellness market with a new acquisition following the High Times deal.
The new acquisition by Lucy Scientific Discovery could potentially expand its market reach, suggesting a positive short-term impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Mind Medicine (MNMD) closed at $4.17, up from $4.00 on Friday 8 and $4.09 on Friday 1.
The stock price of Mind Medicine has increased over the week, suggesting a positive short-term impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100